Who
Lota S. Zoth
Director
Company insider
Files Form 4 as: Director, enGene Therapeutics; Director, Inovio Pharmaceuticals; Director, First Financial Bankshares; Director, 89bio; Director, Lumos Pharma; Director, Zymeworks; Director, Zymeworks; Chief Scientific Officer, Spark Therapeutics.
In numbers
- Trades disclosed
- 153
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $84K
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 23 Feb 2006
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 20 May 2026filed 21 May 2026 | INO Inovio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,800 at $0.00 | filing |
| 20 May 2026filed 21 May 2026 | INO Inovio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,200 at $0.00 | filing |
| 20 May 2026filed 21 May 2026 | INO Inovio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,800 at $0.00 | filing |
| 20 May 2026filed 21 May 2026 | INO Inovio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,200 at $0.00 | filing |
| 28 Apr 2026filed 5 May 2026 | FFIN First Financial BanksharesRegional banks | SEC FORM 4 Code A | —2,142 at $0.00 | filing |
| 28 Apr 2026filed 5 May 2026 | FFIN First Financial BanksharesRegional banks | SEC FORM 4 Code A | —2,142 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —12,500 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —25,000 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —27,400 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —45,150 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —56,400 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 21 May 2025filed 21 May 2025 | INO Inovio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,167 at $0.00 | filing |
| 21 May 2025filed 21 May 2025 | INO Inovio PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,167 | filing |
| 3 Feb 2025filed 5 Feb 2025 | 89biooption or derivative | SEC FORM 4 Code A | —56,400 at $0.00 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —3,345 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —3,328 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.